Targeted therapies: pancreatic neuroendocrine tumors join the club

In the RADIANT-3 study, a randomised, placebo-controlled phase 3 trial, James Yao (Houston, TX, USA) and colleagues assessed the efficacy and safety of everolimus (an inhibitor of the mTOR pathway) plus best supportive care versus placebo plus best supportive care in 410 patients with advanced intermediate or low-grade pancreatic neuroendocrine tumours (PNET) with disease progression within the previous 12 months. Everolimus showed a significant improvement in progression-free survival—the primary endpoint—over placebo, with a median progression-free survival of 11 months for everolimus compared with 4·6 months for placebo (HR 0·35, 95% CI 0·27–0·45, p<0·0001). The Lancet Oncology reports.

http://www.thelancet.com/journals/lanonc/issue/current